A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome

References

• Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf. 2014;5(5):201–213. doi: 10.1177/2042098614548857
   PubMedGoogle Scholar
• Kotb MAM, Ragab H, Elwan YA, et al. Oral contraceptive pills use and adverse effects. Egypt J Hosp Med. 2022;86(1):286–290. doi: 10.21608/ejhm.2022.211984
   Google Scholar
• Casado-Espada NM, de Alarcon R, de la Iglesia-Larrad JI, et al. Hormonal contraceptives, female sexual dysfunction, and managing strategies: a review. J Clin Med. 2019 Jun 25;8(6):908. doi: 10.3390/jcm8060908
   PubMed Web of Science ®Google Scholar
• Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014 Jan;20(1):76–105. doi: 10.1093/humupd/dmt038
   PubMed Web of Science ®Google Scholar
• Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med. 2001 Dec;19(4):295–303. doi: 10.1055/s-2001-18637
   PubMed Web of Science ®Google Scholar
• Samanta MM, Maiti M. Effects of oral contraceptive pill on female health. Int J Exp Res Rev. 2022;28:15–24. doi: 10.52756/ijerr.2022.v28.003
   Google Scholar
• Maguire KW, Westhoff C. The state of hormonal contraception today: established and emerging non-contraceptive health benefits. Am J Obstet Gynecol. 2011;205(4):S4–SS8. doi: 10.1016/j.ajog.2011.06.056
   PubMed Web of Science ®Google Scholar
• Basciani S, Porcaro G. Counteracting side effects of combined oral contraceptives through the administration of specific micronutrients. Eur Rev Med Pharmacol Sci. 2022 Jul;26(13):4846–4862. doi: 10.26355/eurrev_202207_29210
   PubMed Web of Science ®Google Scholar
• Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007 Oct;76(4):267–272. doi: 10.1016/j.contraception.2007.06.008
   PubMed Web of Science ®Google Scholar
• Goshtasebi A, Subotic Brajic T, Scholes D, et al. Adolescent use of combined hormonal contraception and peak bone mineral density accrual: a meta-analysis of international prospective controlled studies. Clin Endocrinol (Oxf). 2019 Apr;90(4):517–524. doi: 10.1111/cen.13932
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Rodriguez-Martinez MA, Spoletini I, et al. Obesity and contraceptive use: impact on cardiovascular risk. ESC Heart Fail. 2022 Dec;9(6):3761–3767. doi: 10.1002/ehf2.14104
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol. 2007 Apr;196(4):412 e1–6. doi: 10.1016/j.ajog.2006.12.015
   PubMed Web of Science ®Google Scholar
• Asare GA, Santa S, Ngala RA, et al. Effect of hormonal contraceptives on lipid profile and the risk indices for cardiovascular disease in a Ghanaian community. Int J Womens Health. 2014;6:597–603. doi: 10.2147/IJWH.S59852
   PubMedGoogle Scholar
• Sitruk-Ware RN, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24. doi: 10.1016/j.beem.2012.09.004
   PubMed Web of Science ®Google Scholar
• Haarala A, Eklund C, Pessi T, et al. Use of combined oral contraceptives alters metabolic determinants and genetic regulation of C-reactive protein. The cardiovascular risk in young finns study. Scand J Clin Lab Invest. 2009;69(2):168–174. doi: 10.1080/00365510802449642
   PubMed Web of Science ®Google Scholar
• Wang Q, Wurtz P, Auro K, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016 Oct;45(5):1445–1457. doi: 10.1093/ije/dyw147
   PubMed Web of Science ®Google Scholar
• Azizi F, Ainy E, Mirmiran P, et al. Contraceptive methods and risk factors of cardiovascular diseases in tehranian women: Tehran lipid and glucose study. Eur J Contracept Reprod Health Care. 2002 Mar;7(1):1–6. doi: 10.1080/ejc.7.1.1.6
   PubMed Web of Science ®Google Scholar
• Naz F, Jyoti S, Akhtar N, et al. Lipid profile of women using oral contraceptive pills. Pak J Biol Sci. 2012 Oct 1;15(19):947–950. doi: 10.3923/pjbs.2012.947.950
   PubMedGoogle Scholar
• Hashemi SJ, Khezri R, Saki N, et al. Association between oral contraceptives with lipid profile: results from Hoveyzeh cohort study (HCS). BMC Women's Health. 2023 Oct 24;23(1):552. doi: 10.1186/s12905-023-02703-7
   PubMed Web of Science ®Google Scholar
• Forslund M, Melin J, Alesi S, et al. Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023 Jul 20;189(1):S1–S16. doi: 10.1093/ejendo/lvad082
   PubMed Web of Science ®Google Scholar
• Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: a systematic review. Contraception. 2016 Dec;94(6):590–604. doi: 10.1016/j.contraception.2016.05.014
   PubMed Web of Science ®Google Scholar
• Danielle B, Cooper PP, Heba M. Oral contraceptive pills. StatPearls. 2022.
   Google Scholar
• Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol. 2009 Jan 20;53(3):221–231. doi: 10.1016/j.jacc.2008.09.042
   PubMed Web of Science ®Google Scholar
• de Wit AE, Booij SH, Giltay EJ, et al. Association of use of oral contraceptives with depressive symptoms among adolescents and young women. JAMA Psychiatry. 2020 Jan 1;77(1):52–59. doi: 10.1001/jamapsychiatry.2019.2838
   PubMed Web of Science ®Google Scholar
• K J. Depression as a side effect of the contraceptive pill. Expert Opin Drug Saf. 2007;6(4):371–374. doi: 10.1517/14740338.6.4.371
   PubMed Web of Science ®Google Scholar
• McKetta S, Keyes KM. Oral contraceptive use and depression among adolescents. Ann Epidemiol. 2019 Jan;29:46–51. doi: 10.1016/j.annepidem.2018.10.002
   PubMed Web of Science ®Google Scholar
• Wang J, Um P, Dickerman BA, et al. Zinc, magnesium, selenium and depression: a review of the evidence, potential mechanisms and implications. Nutrients. 2018 May 9;10(5):584. doi: 10.3390/nu10050584
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24;352(12):1223–1236. doi: 10.1056/NEJMra041536
   PubMed Web of Science ®Google Scholar
• Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod. 2007 Feb;22(2):317–322. doi: 10.1093/humrep/del407
   PubMed Web of Science ®Google Scholar
• Group. REA-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility And Sterility. 2004;81(1):19–25. doi: 10.1016/j.fertnstert.2003.10.004
   Web of Science ®Google Scholar
• Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023 Oct;120(4):767–793. doi: 10.1016/j.fertnstert.2023.07.025
   PubMed Web of Science ®Google Scholar
• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602–1618. doi: 10.1093/humrep/dey256
   PubMed Web of Science ®Google Scholar
• Myers SH, Russo M, Dinicola S, et al. Questioning PCOS phenotypes for reclassification and tailored therapy. Trends Endocrinol Metab. 2023 Nov;34(11):694–703. doi: 10.1016/j.tem.2023.08.005
   PubMed Web of Science ®Google Scholar
• Unfer V, Kandaraki E, Pkhaladze L, et al. When one size does not fit all: reconsidering PCOS etiology, diagnosis, clinical subgroups, and subgroup-specific treatments endocrine and metabolic science. Endocr And Metabolic Sci. 2024;14:14. doi: 10.1016/j.endmts.2024.100159
   Google Scholar
• Norman RJ, Morman R, Teede HJ. “Tis but thy name that is my enemy”-the problem with the naming of polycystic ovary syndrome. Fertil Steril. 2023 Aug;120(2):249–250. doi: 10.1016/j.fertnstert.2023.03.028
   PubMed Web of Science ®Google Scholar
• Myers SH, Montanino Oliva M, Nordio M, et al. PCOS phenotype focus: phenotype D under the magnifying glass. Arch Gynecol Obstet. 2024 Mar 19;309(6):2307–2313. doi: 10.1007/s00404-024-07408-2
   PubMedGoogle Scholar
• Yousuf SD, Ganie MA, Urwat U, et al. Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women. BMC Women's Health. 2023 Feb 15;23(1):68. doi: 10.1186/s12905-023-02187-5
   PubMed Web of Science ®Google Scholar
• Kebapcilar L, Taner CE, Kebapcilar AG, et al. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet. 2009 Aug;280(2):187–193. doi: 10.1007/s00404-008-0884-0
   PubMed Web of Science ®Google Scholar
• Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014 Oct;127(10):912–919. doi: 10.1016/j.amjmed.2014.04.017
   PubMed Web of Science ®Google Scholar
• Gao L, Zhao Y, Wu H, et al. Polycystic ovary syndrome fuels cardiovascular inflammation and aggravates ischemic cardiac injury. Circulation. 2023 Dec 12;148(24):1958–1973. doi: 10.1161/CIRCULATIONAHA.123.065827
   PubMed Web of Science ®Google Scholar
• Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000 Nov 15;152(10):897–907. doi: 10.1093/aje/152.10.897
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Haznedaroglu IC, Kirazli S, et al. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002 Aug;87(8):3871–3875. doi: 10.1210/jcem.87.8.8716
   PubMed Web of Science ®Google Scholar
• Stegenga ME, van der Crabben SN, Levi M, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 2006 Jun;55(6):1807–1812. doi: 10.2337/db05-1543
   PubMed Web of Science ®Google Scholar
• Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost. 2013 Oct;110(4):669–680. doi: 10.1160/TH13-01-0075
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl. 2005 May;6(2):7–14. doi: 10.1016/j.atherosclerosissup.2005.02.003
   PubMed Web of Science ®Google Scholar
• Hong X, Zhang X, You L, et al. Association between adiponectin and newly diagnosed type 2 diabetes in population with the clustering of obesity, dyslipidaemia and hypertension: a cross-sectional study. BMJ Open. 2023 Feb 24;13(2):e060377. doi: 10.1136/bmjopen-2021-060377
   PubMed Web of Science ®Google Scholar
• Manzoor S, Ganie MA, Amin S, et al. Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with polycystic ovarian syndrome: an observational study. Sci Rep. 2019 Jul 15;9(1):10182. doi: 10.1038/s41598-019-46644-4
   PubMedGoogle Scholar
• Abdalla MMI. Role of visfatin in obesity-induced insulin resistance. World J Clin Cases. 2022 Oct 26;10(30):10840–10851. doi: 10.12998/wjcc.v10.i30.10840
   PubMed Web of Science ®Google Scholar
• Kalyan S, Patel MS, Kingwell E, et al. Competing factors link to bone health in polycystic ovary syndrome: chronic low-grade inflammation takes a toll. Sci Rep. 2017 Jun 13;7(1):3432. doi: 10.1038/s41598-017-03685-x
   PubMedGoogle Scholar
• Sarahian N, Noroozzadeh M, Saei Ghare Naz M, et al. Is there any association between migraine headache and polycystic ovary syndrome (PCOS)? A review article. Mol Biol Rep. 2022 Jan;49(1):595–603. doi: 10.1007/s11033-021-06799-8
   PubMed Web of Science ®Google Scholar
• Torre F, Calogero AE, Condorelli RA, et al. Effects of oral contraceptives on thyroid function and vice versa. J Endocrinol Invest. 2020 Sep;43(9):1181–1188. doi: 10.1007/s40618-020-01230-8
   PubMed Web of Science ®Google Scholar
• Glintborg D, Rubin KH, Nybo M, et al. Increased risk of thyroid disease in Danish women with polycystic ovary syndrome: a cohort study. Endocr Connect. 2019 Oct 1;8(10):1405–1415. doi: 10.1530/EC-19-0377
   PubMed Web of Science ®Google Scholar
• Cantelmi T, Lambiase E, Unfer VR, et al. Inositol treatment for psychological symptoms in polycystic ovary syndrome women. Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2383–2389. doi: 10.26355/eurrev_202103_25278
   PubMed Web of Science ®Google Scholar
• Unfer V, Russo M, Aragona C, et al. Treatment with myo-inositol does not improve the clinical features in all PCOS phenotypes. Biomedicines. 2023 Jun 19;11(6):1759. doi: 10.3390/biomedicines11061759
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Perini D, Russo M, et al. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017 Jan;33(1):39–42. doi: 10.1080/09513590.2016.1236078
   PubMed Web of Science ®Google Scholar
• Pustotina O, Myers SH, Unfer V, et al. The effects of myo-inositol and D-Chiro-inositol in a ratio 40: 1 on hormonal and metabolic profile in women with polycystic ovary syndrome classified as phenotype a by the Rotterdam criteria and EMS-Type 1 by the EGOI criteria. Gynecol Obstet Invest. 2024;89(2):131–139. doi: 10.1159/000536163
   PubMed Web of Science ®Google Scholar
• Kamenov Z, Gateva A. Inositols in PCOS. Molecules. 2020 Nov 27;25(23):5566. doi: 10.3390/molecules25235566
   PubMed Web of Science ®Google Scholar
• de Zegher FI. Leader vs follower in the tango of polycystic ovary syndrome: Insulin resistance vs androgen excess. Acta Obstet Gynecol Scand. 2024. doi: 10.1111/aogs.14802
   PubMed Web of Science ®Google Scholar
• Dinicola S, Unfer V, Facchinetti F, et al. Inositols: from established knowledge to novel approaches. Int J Mol Sci. 2021 Sep 30;22(19):10575. doi: 10.3390/ijms221910575
   PubMed Web of Science ®Google Scholar
• Pkhaladze L, Russo M, Unfer V, et al. Treatment of lean PCOS teenagers: a follow-up comparison between myo-inositol and oral contraceptives. Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7476–7485. doi: 10.26355/eurrev_202112_27447
   PubMed Web of Science ®Google Scholar
• Essah PA, Arrowood JA, Cheang KI, et al. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil Steril. 2011 Aug;96(2):501–4 e2. doi: 10.1016/j.fertnstert.2011.05.091
   PubMed Web of Science ®Google Scholar